Index RUT P/E - EPS (ttm) -2.67 Insider Own 52.09% Shs Outstand 181.36M Perf Week 0.19%
Market Cap 7.74B Forward P/E - EPS next Y -2.79 Insider Trans -0.48% Shs Float 87.15M Perf Month 0.90%
Income -432.84M PEG - EPS next Q -0.64 Inst Own 48.53% Short Float 9.09% Perf Quarter 1.67%
Sales 0.00M P/S - EPS this Y 6.16% Inst Trans 4.98% Short Ratio 5.63 Perf Half Y 67.85%
Book/sh 3.71 P/B 11.45 EPS next Y -11.34% ROA -38.29% Short Interest 7.92M Perf Year 33.30%
Cash/sh 5.45 P/C 7.81 EPS next 5Y - ROE -72.44% 52W Range 19.59 - 43.59 Perf YTD 0.35%
Dividend Est. - P/FCF - EPS past 5Y - ROI -37.60% 52W High -2.39% Beta 1.47
Dividend TTM - Quick Ratio 10.92 Sales past 5Y 0.00% Gross Margin - 52W Low 117.20% ATR (14) 0.35
Dividend Ex-Date - Current Ratio 10.92 EPS Y/Y TTM -15.07% Oper. Margin 0.00% RSI (14) 58.87 Volatility 0.79% 0.83%
Employees 334 Debt/Eq 0.71 Sales Y/Y TTM - Profit Margin - Recom 2.67 Target Price 45.00
Option/Short Yes / Yes LT Debt/Eq 0.71 EPS Q/Q -28.02% Payout - Rel Volume 0.64 Prev Close 42.59
Sales Surprise - EPS Surprise 2.74% Sales Q/Q - Earnings Nov 01 BMO Avg Volume 1.41M Price 42.55
SMA20 0.99% SMA50 1.47% SMA200 28.45% Trades
Volume 907,408 Change -0.09%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-08-23 Downgrade TD Cowen
Outperform → Market Perform
$45
Nov-20-23 Resumed JP Morgan
Neutral
$25
Sep-28-23 Initiated Piper Sandler
Overweight
$33
Aug-03-23 Downgrade BofA Securities
Buy → Neutral
$36 → $31
May-04-23 Upgrade Wells Fargo
Equal Weight → Overweight
$30
Apr-10-23 Initiated TD Cowen
Outperform
Mar-17-23 Downgrade JP Morgan
Overweight → Neutral
$40 → $29
Mar-16-23 Resumed Berenberg
Hold
$22
Feb-23-23 Downgrade Wells Fargo
Overweight → Equal Weight
$38 → $30
Nov-01-22 Initiated Loop Capital
Buy
$40
Oct-20-22 Initiated BofA Securities
Buy
$39
Sep-29-22 Initiated Cantor Fitzgerald
Overweight
$41
Sep-26-22 Initiated Wells Fargo
Overweight
$38
Sep-13-22 Initiated Evercore ISI
Outperform
Jul-07-22 Initiated Mizuho
Neutral
$30
Feb-15-22 Initiated Goldman
Neutral
$27
Jan-05-22 Initiated JP Morgan
Overweight
$50
Dec-16-21 Initiated H.C. Wainwright
Buy
$50
Jun-18-21 Initiated Morgan Stanley
Overweight
$27
Dec-10-20 Initiated Goldman
Buy
$24
Show Previous Ratings
Apr-18-24 12:18PM
(The Wall Street Journal)
06:30AM
Mar-17-24 08:50AM
Jan-29-24 02:23PM
Jan-24-24 09:45AM
08:30AM
Loading…
08:30AM
Jan-23-24 02:45PM
Jan-02-24 06:10PM
Dec-08-23 07:00AM
(The Wall Street Journal)
Dec-07-23 04:20PM
(The Wall Street Journal) +11.37%
12:53PM
(The Wall Street Journal)
10:04AM
Dec-06-23 04:46PM
(The Wall Street Journal)
04:30PM
Nov-29-23 06:30AM
06:30AM
Loading…
Nov-08-23 06:30AM
Nov-01-23 09:14AM
06:30AM
Oct-13-23 06:30AM
Oct-11-23 10:45PM
04:01PM
Aug-29-23 06:30AM
Aug-11-23 02:21PM
Aug-08-23 06:28AM
Aug-02-23 06:30AM
Jul-05-23 06:30AM
Jun-15-23 06:30AM
May-10-23 06:30AM
May-03-23 06:30AM
Apr-26-23 10:01AM
06:30AM
Loading…
06:30AM
Apr-11-23 06:30AM
Mar-21-23 06:30AM
Mar-02-23 06:30AM
Feb-22-23 06:30AM
Feb-01-23 06:30AM
Jan-09-23 06:30AM
Jan-04-23 06:30AM
Dec-31-22 07:55AM
Dec-19-22 06:30AM
Dec-15-22 06:30PM
Nov-11-22 06:30AM
Nov-08-22 06:30AM
Oct-19-22 06:30AM
Sep-06-22 06:30AM
Aug-12-22 06:00AM
06:00AM
Aug-10-22 04:01PM
04:01PM
Aug-01-22 06:15AM
Jul-25-22 05:00PM
Jun-15-22 06:30AM
May-25-22 06:30AM
May-11-22 07:38AM
May-10-22 06:30AM
Apr-28-22 06:00AM
Apr-13-22 06:30AM
Mar-31-22 06:30AM
Mar-21-22 06:30AM
Mar-01-22 06:30AM
Feb-16-22 06:30AM
Feb-15-22 12:50PM
06:30AM
Jan-10-22 06:30AM
Jan-06-22 09:38AM
Jan-03-22 07:00AM
Dec-21-21 05:50AM
Dec-16-21 07:00AM
Nov-10-21 06:30AM
Nov-01-21 06:30AM
Oct-20-21 06:30AM
Oct-07-21 07:00AM
Sep-21-21 05:00PM
Sep-15-21 12:11PM
12:09PM
Sep-10-21 07:00AM
Sep-01-21 07:00AM
Aug-12-21 10:37AM
Aug-11-21 06:30AM
Aug-02-21 01:04PM
Jul-30-21 07:00AM
Jul-22-21 07:00AM
Jul-01-21 09:50PM
Jun-29-21 04:24PM
06:30AM
Jun-24-21 01:44AM
Jun-23-21 07:49PM
Jun-15-21 07:00AM
May-27-21 07:00AM
May-17-21 06:30AM
06:15AM
May-04-21 07:00AM
Apr-29-21 07:00AM
Apr-21-21 07:00AM
Apr-13-21 06:30AM
Mar-24-21 06:30AM
06:15AM
Mar-22-21 07:00AM
Feb-24-21 07:00AM
Jan-29-21 12:14AM
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
COLES N ANTHONY Director Apr 01 '24 Option Exercise 3.50 50,000 175,000 65,638 Apr 03 04:15 PM COLES N ANTHONY Director Apr 01 '24 Sale 42.33 50,000 2,116,640 15,638 Apr 03 04:15 PM COLES N ANTHONY Director Mar 04 '24 Option Exercise 3.50 50,000 175,000 65,638 Mar 06 04:15 PM COLES N ANTHONY Director Mar 04 '24 Sale 41.01 50,000 2,050,550 15,638 Mar 06 04:15 PM COLES N ANTHONY Director Feb 29 '24 Option Exercise 3.50 50,000 175,000 65,638 Mar 04 05:49 PM COLES N ANTHONY Director Feb 29 '24 Sale 41.16 50,000 2,057,890 15,638 Mar 04 05:49 PM COLES N ANTHONY Director Feb 07 '24 Sale 41.54 2,506 104,110 15,638 Feb 08 07:14 PM Renger John Chief Scientific Officer Feb 07 '24 Sale 41.54 2,161 89,777 6,370 Feb 08 07:19 PM COLES N ANTHONY Director Jan 02 '24 Option Exercise 3.50 50,000 175,000 52,704 Jan 04 04:15 PM COLES N ANTHONY Director Jan 02 '24 Sale 42.24 50,000 2,111,815 2,704 Jan 04 04:15 PM Sanchez Ramiro Chief Medical Officer Dec 26 '23 Option Exercise 3.50 10,000 35,000 24,673 Dec 28 04:15 PM Tregoning Kathleen See Remarks Dec 26 '23 Option Exercise 10.05 3,150 31,658 10,666 Dec 28 04:15 PM Sanchez Ramiro Chief Medical Officer Dec 26 '23 Sale 42.47 10,000 424,700 14,673 Dec 28 04:15 PM DiPietro Kenneth Chief Human Resources Officer Dec 22 '23 Option Exercise 3.50 8,000 28,000 32,663 Dec 27 04:15 PM DiPietro Kenneth Chief Human Resources Officer Dec 22 '23 Sale 41.45 8,000 331,608 24,663 Dec 27 04:15 PM ALTSCHULLER Susan Chief Financial Officer Dec 20 '23 Sale 41.42 13,808 571,972 16,913 Dec 21 08:12 PM Sanchez Ramiro Chief Medical Officer Dec 20 '23 Sale 41.42 10,152 420,528 14,673 Dec 21 08:14 PM Bodenrader Mark See Remarks Dec 20 '23 Sale 41.42 7,889 326,788 17,724 Dec 21 08:27 PM Akamine Scott Chief Legal Officer Dec 20 '23 Sale 41.42 7,072 292,945 7,237 Dec 21 08:21 PM Tregoning Kathleen See Remarks Dec 20 '23 Sale 41.42 6,288 260,469 7,516 Dec 21 08:10 PM DiPietro Kenneth Chief Human Resources Officer Dec 20 '23 Sale 41.42 6,256 259,144 24,663 Dec 21 08:24 PM Sanchez Ramiro Chief Medical Officer Dec 15 '23 Option Exercise 9.88 7,500 74,100 7,500 Dec 19 04:15 PM Sanchez Ramiro Chief Medical Officer Dec 15 '23 Sale 41.39 7,500 310,393 0 Dec 19 04:15 PM Akamine Scott Chief Legal Officer Dec 07 '23 Option Exercise 13.17 10,000 131,700 10,513 Dec 07 07:45 PM Sanchez Ramiro Chief Medical Officer Dec 07 '23 Option Exercise 3.50 10,000 35,000 10,000 Dec 11 04:17 PM Sanchez Ramiro Chief Medical Officer Dec 07 '23 Sale 41.37 10,000 413,700 0 Dec 11 04:17 PM Akamine Scott Chief Legal Officer Dec 07 '23 Sale 41.37 10,000 413,700 513 Dec 07 07:45 PM Akamine Scott Chief Legal Officer Dec 05 '23 Option Exercise 13.17 7,500 98,775 8,013 Dec 07 07:45 PM Akamine Scott Chief Legal Officer Dec 05 '23 Sale 35.00 7,500 262,500 513 Dec 07 07:45 PM COLES N ANTHONY Director Nov 14 '23 Option Exercise 3.50 22,824 79,884 25,528 Nov 16 04:15 PM COLES N ANTHONY Director Nov 14 '23 Sale 25.13 22,824 573,455 2,704 Nov 16 04:15 PM COLES N ANTHONY Director Nov 08 '23 Option Exercise 3.50 100 350 2,804 Nov 09 05:03 PM COLES N ANTHONY Director Nov 08 '23 Sale 25.16 100 2,516 2,704 Nov 09 05:03 PM COLES N ANTHONY Director Nov 07 '23 Option Exercise 3.50 27,076 94,766 29,780 Nov 09 05:03 PM COLES N ANTHONY Director Nov 07 '23 Sale 25.02 27,076 677,555 2,704 Nov 09 05:03 PM COLES N ANTHONY Director Nov 03 '23 Option Exercise 3.50 61,401 214,904 64,105 Nov 06 05:12 PM COLES N ANTHONY Director Nov 03 '23 Sale 25.43 61,401 1,561,458 2,704 Nov 06 05:12 PM COLES N ANTHONY Director Nov 02 '23 Option Exercise 3.50 38,599 135,096 41,303 Nov 06 05:12 PM COLES N ANTHONY Director Nov 02 '23 Sale 25.19 38,599 972,239 2,704 Nov 06 05:12 PM PATRICK DEVAL L Director Nov 01 '23 Option Exercise 12.62 30,130 380,241 33,412 Nov 03 04:15 PM PATRICK DEVAL L Director Nov 01 '23 Sale 25.00 30,130 753,250 3,282 Nov 03 04:15 PM BAIN CAPITAL INVESTORS LLC 10% Owner Oct 16 '23 Buy 22.81 5,480,052 124,999,986 65,679,781 Oct 18 04:30 PM Koppel Adam Director Oct 16 '23 Buy 22.81 5,480,052 124,999,986 65,679,781 Oct 18 04:30 PM Gordon Christopher R Director Oct 16 '23 Buy 22.81 5,480,052 124,999,986 65,679,781 Oct 18 04:30 PM PERCEPTIVE ADVISORS LLC Director Oct 16 '23 Buy 22.81 876,808 19,999,990 10,794,876 Oct 17 04:53 PM COLES N ANTHONY Director Sep 07 '23 Option Exercise 3.50 50,000 175,000 52,704 Sep 08 04:35 PM COLES N ANTHONY Director Sep 07 '23 Sale 24.07 50,000 1,203,415 2,704 Sep 08 04:35 PM Burgess Paul D. See Remarks Aug 04 '23 Buy 22.93 21,880 501,794 21,880 Aug 07 05:11 PM Renaud Ronald C JR President & CEO Aug 03 '23 Buy 23.96 83,857 2,008,811 83,857 Aug 07 05:13 PM COLES N ANTHONY Director Jul 11 '23 Option Exercise 3.50 50,000 175,000 52,704 Jul 13 05:41 PM COLES N ANTHONY Director Jul 11 '23 Sale 30.03 50,000 1,501,340 2,704 Jul 13 05:41 PM DEKKERS MARIJN E Director Jun 15 '23 Sale 34.43 200,000 6,886,000 402,326 Jun 20 04:56 PM Bodenrader Mark See Remarks Jun 02 '23 Sale 32.95 1,895 62,440 5,522 Jun 05 08:07 PM COLES N ANTHONY CEO and Chairperson Jun 01 '23 Option Exercise 3.50 50,000 175,000 52,704 Jun 05 08:12 PM COLES N ANTHONY CEO and Chairperson Jun 01 '23 Sale 32.60 50,000 1,630,070 2,704 Jun 05 08:12 PM
Index NDX, S&P 500 P/E 28.27 EPS (ttm) 33.85 Insider Own 4.23% Shs Outstand 107.60M Perf Week 8.36%
Market Cap 105.43B Forward P/E 20.19 EPS next Y 47.39 Insider Trans -2.12% Shs Float 105.50M Perf Month 2.13%
Income 3.86B PEG 2.86 EPS next Q 10.58 Inst Own 84.46% Short Float 1.31% Perf Quarter 1.25%
Sales 13.10B P/S 8.05 EPS this Y 0.86% Inst Trans -0.34% Short Ratio 2.93 Perf Half Y 20.94%
Book/sh 244.93 P/B 3.91 EPS next Y 7.31% ROA 11.98% Short Interest 1.39M Perf Year 19.15%
Cash/sh 95.48 P/C 10.02 EPS next 5Y 9.90% ROE 15.28% 52W Range 684.80 - 998.33 Perf YTD 8.96%
Dividend Est. - P/FCF 25.94 EPS past 5Y 10.31% ROI 12.99% 52W High -4.14% Beta 0.11
Dividend TTM - Quick Ratio 4.51 Sales past 5Y 19.99% Gross Margin 83.00% 52W Low 39.75% ATR (14) 21.10
Dividend Ex-Date - Current Ratio 5.27 EPS Y/Y TTM -7.49% Oper. Margin 30.81% RSI (14) 64.09 Volatility 3.00% 2.10%
Employees 13450 Debt/Eq 0.10 Sales Y/Y TTM 5.90% Profit Margin 29.45% Recom 1.83 Target Price 1052.09
Option/Short Yes / Yes LT Debt/Eq 0.10 EPS Q/Q -12.56% Payout 0.00% Rel Volume 1.11 Prev Close 937.61
Sales Surprise -2.49% EPS Surprise -6.11% Sales Q/Q -0.54% Earnings May 02 BMO Avg Volume 472.87K Price 957.00
SMA20 5.26% SMA50 1.35% SMA200 10.30% Trades
Volume 525,987 Change 2.07%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-24 Initiated Bernstein
Outperform
$1125
Jan-12-24 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$884 → $1076
Nov-09-23 Initiated Deutsche Bank
Hold
$800
Nov-03-23 Upgrade Raymond James
Mkt Perform → Outperform
$950
Aug-21-23 Upgrade Canaccord Genuity
Hold → Buy
$720 → $992
Aug-21-23 Reiterated Oppenheimer
Perform
$950 → $1050
Jun-28-23 Downgrade Canaccord Genuity
Buy → Hold
$953 → $720
Mar-27-23 Upgrade SVB Securities
Market Perform → Outperform
$834 → $976
Mar-24-23 Upgrade Jefferies
Hold → Buy
$675 → $925
Mar-23-23 Upgrade Raymond James
Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen
Market Perform → Outperform
$775 → $875
Jan-20-23 Upgrade JP Morgan
Neutral → Overweight
$850
Oct-26-22 Downgrade Raymond James
Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI
Outperform → In-line
$760
Sep-09-22 Upgrade Morgan Stanley
Equal-Weight → Overweight
$625 → $851
Sep-09-22 Upgrade Jefferies
Underperform → Hold
$536 → $675
Jul-25-22 Downgrade SVB Leerink
Outperform → Mkt Perform
$630
Jul-13-22 Initiated Cantor Fitzgerald
Neutral
$625
Jun-06-22 Initiated Jefferies
Underperform
$536
May-23-22 Initiated SVB Leerink
Outperform
$738
Show Previous Ratings
Today 07:38AM
May-03-24 10:20AM
10:15AM
09:56AM
06:15AM
03:10AM
Loading…
03:10AM
01:08AM
May-02-24 04:03PM
(Investor's Business Daily)
02:51PM
01:54PM
01:52PM
10:53AM
10:01AM
09:30AM
08:32AM
07:15AM
Loading…
07:15AM
07:09AM
06:45AM
(Investor's Business Daily)
06:44AM
06:44AM
(Associated Press Finance)
06:39AM
06:34AM
06:30AM
May-01-24 06:42AM
(Pharmaceutical Technology)
Apr-30-24 08:47AM
Apr-29-24 09:35AM
09:16AM
07:00AM
Apr-28-24 06:32PM
Apr-26-24 12:24PM
08:24AM
Loading…
08:24AM
Apr-25-24 11:42AM
(The Wall Street Journal)
10:02AM
08:44AM
08:15AM
07:00AM
07:00AM
03:00AM
Apr-24-24 10:05AM
Apr-22-24 05:54PM
Apr-16-24 12:10PM
Apr-15-24 07:59PM
07:24PM
07:20PM
07:45AM
04:46AM
Apr-12-24 01:54PM
Apr-11-24 04:43PM
02:02PM
(Investor's Business Daily)
01:59PM
(The Wall Street Journal)
01:07PM
01:01PM
(Investor's Business Daily)
12:45PM
(Investor's Business Daily)
08:17AM
07:34AM
07:06AM
Apr-10-24 04:59PM
04:52PM
04:31PM
Apr-09-24 07:37AM
Apr-07-24 04:00PM
Apr-05-24 07:00AM
Apr-03-24 10:03PM
Apr-01-24 04:05PM
Mar-28-24 08:00AM
01:00AM
Mar-26-24 10:37AM
06:44AM
Mar-25-24 07:55AM
07:27AM
07:07AM
07:00AM
Mar-18-24 01:28PM
Mar-17-24 05:20PM
Mar-13-24 10:55AM
Mar-12-24 11:55PM
12:32PM
Mar-11-24 07:00AM
Mar-09-24 05:52AM
Mar-08-24 08:15AM
07:00AM
Mar-05-24 07:31AM
Mar-04-24 04:09PM
Feb-23-24 10:20AM
(Investor's Business Daily)
01:00AM
01:00AM
Feb-22-24 01:55PM
Feb-21-24 10:00AM
07:00AM
Feb-18-24 12:45AM
Feb-16-24 01:00AM
12:59AM
Feb-10-24 08:30AM
Feb-09-24 06:45AM
Feb-06-24 04:05PM
06:45AM
Feb-05-24 07:00AM
(The Wall Street Journal)
Feb-03-24 08:10AM
01:53AM
(Thomson Reuters StreetEvents)
Feb-02-24 03:43PM
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McCourt Marion EVP Commercial May 01 '24 Sale 889.41 250 222,352 12,931 May 03 04:02 PM RYAN ARTHUR F Director May 01 '24 Sale 899.61 100 89,961 18,082 May 03 04:01 PM McCourt Marion EVP Commercial Apr 01 '24 Sale 964.73 250 241,182 13,181 Apr 03 04:05 PM RYAN ARTHUR F Director Apr 01 '24 Sale 962.53 100 96,253 18,182 Apr 03 04:06 PM MURPHY ANDREW J EVP Research Mar 14 '24 Sale 956.47 5,783 5,531,290 48,306 Mar 15 04:01 PM MURPHY ANDREW J EVP Research Mar 13 '24 Option Exercise 399.66 20,000 7,993,200 68,306 Mar 15 04:01 PM McCourt Marion EVP Commercial Mar 01 '24 Sale 967.50 358 346,365 13,431 Mar 05 04:01 PM RYAN ARTHUR F Director Mar 01 '24 Sale 982.05 100 98,205 18,282 Mar 05 04:01 PM SING GEORGE L Director Feb 26 '24 Option Exercise 413.33 1,000 413,330 26,849 Feb 28 04:04 PM Bassler Bonnie L Director Feb 26 '24 Option Exercise 391.92 854 334,700 2,236 Feb 26 04:07 PM SING GEORGE L Director Feb 26 '24 Sale 992.50 1,000 992,500 26,349 Feb 28 04:04 PM LAROSA JOSEPH J EVP General Counsel and Secret Feb 26 '24 Sale 990.00 1,000 990,000 36,543 Feb 28 04:04 PM Bassler Bonnie L Director Feb 26 '24 Sale 979.25 854 836,280 1,382 Feb 26 04:07 PM SING GEORGE L Director Feb 23 '24 Option Exercise 413.33 500 206,665 26,849 Feb 26 04:07 PM SING GEORGE L Director Feb 23 '24 Sale 985.00 500 492,500 26,349 Feb 26 04:07 PM SING GEORGE L Director Feb 22 '24 Option Exercise 413.33 3,000 1,239,990 27,349 Feb 26 04:07 PM SING GEORGE L Director Feb 22 '24 Sale 965.00 3,000 2,895,000 26,349 Feb 26 04:07 PM LAROSA JOSEPH J EVP General Counsel and Secret Feb 22 '24 Sale 967.65 1,000 967,650 37,543 Feb 26 04:07 PM YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO Feb 15 '24 Option Exercise 399.66 172,723 69,030,474 925,209 Feb 20 04:03 PM Van Plew Daniel P EVP & General Mgr, Industrial Feb 14 '24 Sale 942.28 10,434 9,831,727 20,378 Feb 16 04:15 PM Van Plew Daniel P EVP & General Mgr, Industrial Feb 09 '24 Option Exercise 378.30 35,375 13,382,510 47,153 Feb 13 04:04 PM SING GEORGE L Director Feb 09 '24 Option Exercise 413.33 500 206,665 26,849 Feb 12 04:02 PM Fenimore Christopher R. SVP Finance & CFO Feb 09 '24 Sale 953.31 4,919 4,689,320 14,372 Feb 12 04:02 PM SING GEORGE L Director Feb 09 '24 Sale 955.00 500 477,500 26,349 Feb 12 04:02 PM SING GEORGE L Director Feb 08 '24 Option Exercise 413.33 500 206,665 26,849 Feb 12 04:02 PM SING GEORGE L Director Feb 08 '24 Sale 945.00 500 472,500 26,349 Feb 12 04:02 PM STAHL NEIL EVP Research and Development Feb 07 '24 Sale 950.35 8,037 7,637,954 52,019 Feb 08 04:02 PM LAROSA JOSEPH J EVP General Counsel and Secret Feb 07 '24 Sale 950.00 1,000 950,000 38,543 Feb 09 04:12 PM McCourt Marion EVP Commercial Feb 05 '24 Sale 934.71 1,000 934,710 13,789 Feb 06 04:08 PM STAHL NEIL EVP Research and Development Feb 02 '24 Option Exercise 399.66 30,750 12,289,545 82,769 Feb 06 04:08 PM Landry Robert E EVP Finance CFO Feb 02 '24 Option Exercise 378.98 400 151,592 23,974 Feb 06 04:08 PM McCourt Marion EVP Commercial Feb 01 '24 Sale 945.61 273 258,152 14,789 Feb 02 04:02 PM RYAN ARTHUR F Director Feb 01 '24 Sale 954.22 100 95,422 18,382 Feb 05 04:05 PM Landry Robert E EVP Finance CFO Jan 31 '24 Option Exercise 378.98 400 151,592 23,856 Feb 02 04:02 PM Bassler Bonnie L Director Jan 30 '24 Option Exercise 380.95 827 315,046 2,209 Jan 31 04:52 PM Bassler Bonnie L Director Jan 30 '24 Sale 959.00 827 793,093 1,382 Jan 31 04:52 PM Landry Robert E EVP Finance CFO Jan 24 '24 Option Exercise 378.98 500 189,490 23,808 Jan 25 04:17 PM Fenimore Christopher R. SVP Controller Jan 23 '24 Option Exercise 477.67 10,000 4,776,650 22,874 Jan 25 04:17 PM GOLDSTEIN JOSEPH L Director Jan 23 '24 Option Exercise 625.60 2,707 1,693,499 9,089 Jan 25 04:18 PM Landry Robert E EVP Finance CFO Jan 23 '24 Option Exercise 378.98 1,100 416,878 24,084 Jan 25 04:17 PM GOLDSTEIN JOSEPH L Director Jan 23 '24 Sale 950.00 2,707 2,571,650 6,382 Jan 25 04:18 PM Landry Robert E EVP Finance CFO Jan 17 '24 Option Exercise 378.98 500 189,490 23,338 Jan 18 04:02 PM Landry Robert E EVP Finance CFO Jan 12 '24 Option Exercise 378.98 800 303,184 23,406 Jan 17 04:03 PM Landry Robert E EVP Finance CFO Jan 04 '24 Option Exercise 378.98 500 189,490 22,948 Jan 08 04:02 PM LAROSA JOSEPH J EVP General Counsel and Secret Jan 03 '24 Option Exercise 399.66 34,000 13,588,440 64,036 Jan 04 04:19 PM Fenimore Christopher R. SVP Controller Jan 03 '24 Option Exercise 477.67 10,000 4,776,650 20,329 Jan 04 04:22 PM Landry Robert E EVP Finance CFO Jan 03 '24 Option Exercise 378.98 1,100 416,878 23,136 Jan 04 04:19 PM Bassler Bonnie L Director Jan 03 '24 Option Exercise 380.95 826 314,665 2,208 Jan 04 04:11 PM Bassler Bonnie L Director Jan 03 '24 Sale 914.00 826 754,964 1,382 Jan 04 04:11 PM Zoghbi Huda Y Director Jan 02 '24 Option Exercise 391.92 1,117 437,775 2,364 Jan 04 04:11 PM Landry Robert E EVP Finance CFO Jan 02 '24 Option Exercise 378.98 650 246,337 22,457 Jan 04 04:19 PM YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO Jan 02 '24 Sale 900.00 16,848 15,163,200 180,000 May 01 04:00 PM YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO Jan 02 '24 Sale 900.00 16,848 15,163,200 180,000 Jan 04 04:20 PM Zoghbi Huda Y Director Jan 02 '24 Sale 900.00 1,117 1,005,300 1,247 Jan 04 04:11 PM McCourt Marion EVP Commercial Jan 02 '24 Sale 873.91 274 239,451 15,062 Jan 04 04:17 PM RYAN ARTHUR F Director Jan 02 '24 Sale 899.90 100 89,990 18,347 Jan 04 04:08 PM Landry Robert E EVP Finance CFO Dec 28 '23 Option Exercise 378.98 850 322,133 22,419 Dec 29 04:05 PM BROWN MICHAEL S Director Dec 27 '23 Option Exercise 482.68 2,049 989,011 3,296 Dec 29 04:06 PM Landry Robert E EVP Finance CFO Dec 27 '23 Option Exercise 378.98 750 284,235 22,111 Dec 29 04:05 PM Fenimore Christopher R. SVP Controller Dec 27 '23 Sale 856.71 2,448 2,097,226 14,372 Dec 29 04:04 PM BROWN MICHAEL S Director Dec 27 '23 Sale 898.00 2,049 1,840,002 1,247 Dec 29 04:06 PM Fenimore Christopher R. SVP Controller Dec 22 '23 Sale 846.27 250 211,568 16,820 Dec 26 04:08 PM Fenimore Christopher R. SVP Controller Dec 21 '23 Sale 844.01 1,680 1,417,934 17,070 Dec 26 04:08 PM Landry Robert E EVP Finance CFO Dec 13 '23 Option Exercise 378.98 1,000 378,980 22,084 Dec 14 04:08 PM Bassler Bonnie L Director Dec 13 '23 Option Exercise 376.69 610 229,781 1,857 Dec 14 04:07 PM Bassler Bonnie L Director Dec 13 '23 Sale 870.00 610 530,700 1,247 Dec 14 04:07 PM McCourt Marion EVP Commercial Dec 11 '23 Sale 838.44 270 226,379 20,814 Dec 12 04:04 PM MURPHY ANDREW J EVP Research Dec 05 '23 Sale 817.44 6,536 5,342,787 59,421 Dec 06 04:02 PM MURPHY ANDREW J EVP Research Dec 04 '23 Option Exercise 270.43 20,000 5,408,600 79,421 Dec 06 04:02 PM RYAN ARTHUR F Director Dec 01 '23 Sale 817.30 100 81,730 18,447 Dec 04 04:02 PM MURPHY ANDREW J EVP Research Nov 14 '23 Sale 799.17 6,492 5,188,213 59,421 Nov 15 04:02 PM MURPHY ANDREW J EVP Research Nov 13 '23 Option Exercise 270.43 20,000 5,408,600 79,421 Nov 15 04:02 PM RYAN ARTHUR F Director Nov 07 '23 Sale 827.90 100 82,790 18,547 Nov 08 04:07 PM McCourt Marion EVP Commercial Nov 01 '23 Option Exercise 381.40 1,000 381,400 20,803 Nov 02 04:03 PM McCourt Marion EVP Commercial Nov 01 '23 Sale 783.91 1,000 783,910 19,803 Nov 02 04:03 PM Zoghbi Huda Y Director Oct 13 '23 Option Exercise 391.92 1,000 391,920 2,247 Oct 17 04:06 PM Zoghbi Huda Y Director Oct 13 '23 Sale 850.00 1,000 850,000 1,247 Oct 17 04:06 PM McCourt Marion EVP Commercial Oct 02 '23 Option Exercise 372.46 1,038 386,613 20,841 Oct 03 04:04 PM McCourt Marion EVP Commercial Oct 02 '23 Sale 827.00 1,038 858,426 19,803 Oct 03 04:04 PM McCourt Marion EVP Commercial Sep 01 '23 Sale 834.55 250 208,638 19,803 Sep 06 04:03 PM Van Plew Daniel P EVP & General Mgr, Industrial Aug 24 '23 Sale 841.71 6,197 5,216,073 21,508 Aug 25 04:02 PM Van Plew Daniel P EVP & General Mgr, Industrial Aug 23 '23 Option Exercise 381.40 23,125 8,819,875 44,633 Aug 25 04:02 PM POON CHRISTINE A Director Aug 23 '23 Option Exercise 273.67 12,280 3,360,668 14,317 Aug 25 04:02 PM Fenimore Christopher R. SVP Controller Aug 23 '23 Option Exercise 399.66 7,000 2,797,620 26,140 Aug 25 04:03 PM POON CHRISTINE A Director Aug 23 '23 Sale 839.97 12,280 10,314,829 2,037 Aug 25 04:02 PM Landry Robert E EVP Finance CFO Aug 23 '23 Sale 844.00 223 188,212 31,699 Aug 25 04:02 PM STAHL NEIL EVP Research and Development Aug 22 '23 Sale 840.98 11,665 9,810,082 53,100 Aug 23 04:03 PM STAHL NEIL EVP Research and Development Aug 21 '23 Option Exercise 399.66 50,000 19,983,000 103,100 Aug 23 04:03 PM Bassler Bonnie L Director Aug 21 '23 Option Exercise 391.92 853 334,308 2,100 Aug 23 04:03 PM Bassler Bonnie L Director Aug 21 '23 Sale 829.00 853 707,137 1,247 Aug 23 04:03 PM Bassler Bonnie L Director Aug 10 '23 Option Exercise 391.92 853 334,308 2,100 Aug 11 04:13 PM Bassler Bonnie L Director Aug 10 '23 Sale 789.00 853 673,017 1,247 Aug 11 04:13 PM McCourt Marion EVP Commercial Aug 01 '23 Sale 744.66 250 186,165 20,053 Aug 03 04:02 PM RYAN ARTHUR F Director Aug 01 '23 Sale 736.59 100 73,659 18,647 Aug 03 04:25 PM McCourt Marion EVP Commercial Jul 03 '23 Sale 710.09 250 177,522 20,303 Jul 06 04:02 PM RYAN ARTHUR F Director Jul 03 '23 Sale 716.88 100 71,688 18,747 Jul 06 04:01 PM McCourt Marion EVP Commercial Jun 01 '23 Sale 736.00 250 184,000 20,553 Jun 02 04:12 PM RYAN ARTHUR F Director Jun 01 '23 Sale 735.42 100 73,542 18,847 Jun 02 04:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
